Mechanisms of action of tasquinimod on the tumour microenvironment

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)

(2013) Y. Loriot et al.   ANNALS OF ONCOLOGY

Common Interactions between S100A4 and S100A9 Defined by a Novel Chemical Probe

(2013) Per Björk et al.   PLoS One

Abstract 1551: Targeting myeloid derived suppressor cells as novel strategy to enhance immunotherapy in murine prostate cancer models

(2012) Li Shen et al.   CANCER RESEARCH

S100A9 Is a Novel Ligand of EMMPRIN That Promotes Melanoma Metastasis

(2012) T. Hibino et al.   CANCER RESEARCH

Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment

(2012) J. T. Isaacs et al.   CANCER RESEARCH

A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis

(2012) Swarnali Acharyya et al.   CELL

Targeting the Tumor Microenvironment for Cancer Therapy

(2012) N. E. Sounni et al.   CLINICAL CHEMISTRY

Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives

(2012) Giuseppe Giannini et al.   Future Medicinal Chemistry

Myeloid-Derived Suppressor Cells and anti-tumor T cells: a complex relationship

(2012) Ngozi R. Monu et al.   IMMUNOLOGICAL INVESTIGATIONS

The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor

(2012) Sathish Kasina et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

S100A9 Interaction with TLR4 Promotes Tumor Growth

(2012) Eva Källberg et al.   PLoS One

Myeloid-derived suppressor cells - their role in haemato-oncological malignancies and other cancers and possible implications for therapy

(2011) Tamar Tadmor et al.   BRITISH JOURNAL OF HAEMATOLOGY

Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy

(2011) Eric Tartour et al.   CANCER AND METASTASIS REVIEWS

Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients

(2011) Paola Filipazzi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications

(2011) Omar Khan et al.   IMMUNOLOGY AND CELL BIOLOGY

MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy

(2011) James Finke et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

(2011) Roberto Pili et al.   JOURNAL OF CLINICAL ONCOLOGY

S100A8 and S100A9: New Insights into Their Roles in Malignancy

(2011) Geetha Srikrishna   Journal of Innate Immunity

The Suppressive Tumor Microenvironment: A Challenge in Cancer Immunotherapy

(2011) Elizabeth A. Vasievich et al.   MOLECULAR PHARMACEUTICS

Signaling Pathways Governing Tumor Angiogenesis

(2011) Toshiharu Sakurai et al.   ONCOLOGY

Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050)

(2011) Karin Jennbacken et al.   PROSTATE

Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts

(2011) Susan L. Dalrymple et al.   PROSTATE

Targeting immune suppressing myeloid-derived suppressor cells in oncology

(2010) Johnny Kao et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Histone Deacetylases: Anti-Angiogenic Targets in Cancer Therapy

(2010) D. Mottet et al.   CURRENT CANCER DRUG TARGETS

Evading tumor evasion: Current concepts and perspectives of anti-angiogenic cancer therapy

(2010) Amir Abdollahi et al.   DRUG RESISTANCE UPDATES

The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer

(2010) John T Isaacs   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors

(2010) Anders Olsson et al.   Molecular Cancer

Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer

(2009) O Bratt et al.   BRITISH JOURNAL OF CANCER

Inflammation, Microenvironment, and the Immune System in Cancer Progression

(2009) Andrew Keibel et al.   CURRENT PHARMACEUTICAL DESIGN

Myeloid-derived suppressor cells: A novel therapeutic target

(2009) Jennifer S. Ko et al.   Current Oncology Reports

Identification of Human S100A9 as a Novel Target for Treatment of Autoimmune Disease via Binding to Quinoline-3-Carboxamides

(2009) Per Björk et al.   PLOS BIOLOGY

Targeting tumor angiogenesis with histone deacetylase inhibitors

(2008) Leigh Ellis et al.   CANCER LETTERS

Thrombospondin 1 Promotes Tumor Macrophage Recruitment and Enhances Tumor Cell Cytotoxicity of Differentiated U937 Cells

(2008) G. Martin-Manso et al.   CANCER RESEARCH

The tumor microenvironment and metastatic disease

(2008) Sarah Jane Lunt et al.   CLINICAL & EXPERIMENTAL METASTASIS

Structural and Functional Analysis of the Human HDAC4 Catalytic Domain Reveals a Regulatory Structural Zinc-binding Domain

(2008) Matthew J. Bottomley et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein

(2008) Pingyan Cheng et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A review of the S100 proteins in cancer

(2007) I. Salama et al.   EJSO